TGFA and familial pancreatic carcinoma: In the case of the studies herewith reported, the in vitro and in vivo results demonstrate the potent antitumor activity of ADC that target TGFα, providing a strong rationale for further preclinical and clinical investigation of ADCs targeting proTGFα as a therapeutic strategy for pancreatic cancer.